BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37216268)

  • 1. A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis.
    Ravichandran S; Hall A; Jenner M; Garg M; Kishore B; Lachmann H; Gillmore J; Pitchford A; Oughton JB; Mahmood S; Sachchithantham S; Hawkins P; Brown S; Wechalekar A
    Amyloid; 2023 Sep; 30(3):290-296. PubMed ID: 37216268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
    Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
    Niesvizky R; Martin TG; Bensinger WI; Alsina M; Siegel DS; Kunkel LA; Wong AF; Lee S; Orlowski RZ; Wang M
    Clin Cancer Res; 2013 Apr; 19(8):2248-56. PubMed ID: 23447001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.
    Jelinek T; Kryukova E; Kufova Z; Kryukov F; Hajek R
    Hematol Oncol; 2017 Dec; 35(4):408-419. PubMed ID: 27647123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
    Dimopoulos MA; Moreau P; Palumbo A; Joshua D; Pour L; Hájek R; Facon T; Ludwig H; Oriol A; Goldschmidt H; Rosiñol L; Straub J; Suvorov A; Araujo C; Rimashevskaya E; Pika T; Gaidano G; Weisel K; Goranova-Marinova V; Schwarer A; Minuk L; Masszi T; Karamanesht I; Offidani M; Hungria V; Spencer A; Orlowski RZ; Gillenwater HH; Mohamed N; Feng S; Chng WJ;
    Lancet Oncol; 2016 Jan; 17(1):27-38. PubMed ID: 26671818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
    J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
    Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Gavriatopoulou M; Oriol A; Rabin N; Nooka A; Qi M; Beksac M; Jakubowiak A; Ding B; Zahlten-Kumeli A; Yusuf A; Dimopoulos M
    Lancet Oncol; 2022 Jan; 23(1):65-76. PubMed ID: 34871550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
    Moreau P; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Risse ML; Asset G; Macé S; Martin T;
    Lancet; 2021 Jun; 397(10292):2361-2371. PubMed ID: 34097854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
    Berenson JR; Cartmell A; Bessudo A; Lyons RM; Harb W; Tzachanis D; Agajanian R; Boccia R; Coleman M; Moss RA; Rifkin RM; Patel P; Dixon S; Ou Y; Anderl J; Aggarwal S; Berdeja JG
    Blood; 2016 Jun; 127(26):3360-8. PubMed ID: 27207788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Vesole DH; Bilotti E; Richter JR; McNeill A; McBride L; Raucci L; Anand P; Bednarz U; Ivanovski K; Smith J; Batra V; Aleman A; Sims T; Guerrero L; Mato A; Siegel DS
    Br J Haematol; 2015 Oct; 171(1):52-9. PubMed ID: 26018491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
    Shah JJ; Stadtmauer EA; Abonour R; Cohen AD; Bensinger WI; Gasparetto C; Kaufman JL; Lentzsch S; Vogl DT; Gomes CL; Pascucci N; Smith DD; Orlowski RZ; Durie BG
    Blood; 2015 Nov; 126(20):2284-90. PubMed ID: 26384354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
    Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
    Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
    Wang M; Martin T; Bensinger W; Alsina M; Siegel DS; Kavalerchik E; Huang M; Orlowski RZ; Niesvizky R
    Blood; 2013 Oct; 122(18):3122-8. PubMed ID: 24014245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
    Stewart AK; Rajkumar SV; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Wang M; Maisnar V; Minarik J; Bensinger WI; Mateos MV; Ben-Yehuda D; Kukreti V; Zojwalla N; Tonda ME; Yang X; Xing B; Moreau P; Palumbo A;
    N Engl J Med; 2015 Jan; 372(2):142-52. PubMed ID: 25482145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
    Du J; Fang B; Li J; Jin J; Wang S; Zou D; Cai Z; Wang H; Hu J; Li W; Fu C; Shao Z; Xia Z; Liu P; Niu T; Tang ET; Kimball AS; Hou J; Chen W
    Int J Hematol; 2021 Mar; 113(3):422-429. PubMed ID: 33389656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.
    Manwani R; Mahmood S; Sachchithanantham S; Lachmann HJ; Gillmore JD; Yong K; Rabin N; Popat R; Kyriakou C; Worthington S; Sharpley F; Smith M; Shah R; Cheesman S; Hawkins PN; Wechalekar AD
    Br J Haematol; 2019 Dec; 187(5):638-641. PubMed ID: 31388995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.